Amgen misses Street

Amgen Inc. (NASDAQ:AMGN) reported 1Q14 adjusted diluted EPS of $1.87, missing by $0.07 the Street's estimate of $1.94 and down from $1.96 in 1Q13. First quarter revenues increased 7% to $4.5 billion, but missed the Street's $4.8 billion estimate. Amgen reiterated its 2014 revenue guidance of $19.2-$19.6 billion and adjusted EPS guidance of $7.90-$8.20. The Street was expecting full-year EPS of $8.16 on $19.6 billion in revenues.

Amgen also said it plans to submit U.S. and EU regulatory applications for evolocumab ( AMG 145) this year. The company previously said it was planning global submissions this year for the human mAb against proprotein convertase subtilisin/kexin type 9 (PCSK9), but did not disclose specific markets. ...